Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ReSCInD
NCT05880524Phase 2Recruiting
- Sponsor
- Ludwig Maximilian University of Munich
- Start
- Oct 2026
- Primary completion
- Mar 2028
- Modality
- Replacement Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, single-blind trial of dornase alfa in ischemic stroke (2 arms), sponsored by Ludwig Maximilian University of Munich. Primary endpoint: Interleukin-1 beta concentration. Started Oct 2026; status: recruiting.
02
Drugs
dornase alfa
03
Conditions
ischemic stroke
Beyond the preview
Go deeper on NCT05880524.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05880524.